Several factors underlie the importance of the initiative put forth by this expert panel: there is a rising prevalence of diabetes [98]; half of the T2D population is not at target, among which 61% were receiving insulin therapy [99], suggesting delayed insulin initiation and intensification; there are multiple titration algorithms to choose from which adds to the confusion and complexity for patients and providers; and the arrival of new long-acting basal insulins and other pharmacological and technological advances that require consideration. The gene discussed is INS; the disease is diabetes mellitus.